NPPB and hydrops fetalis: The patients from VICTORIA were at a higher risk than those enrolled in previous clinical HFrEF trials, as indicated by higher median NT-proBNP values (2816 pg/mL vs. 1608 pg/mL in PARADIGM-HF) as well as patients with NYHA class III or IV symptoms (40% vs. 25% in PARADIGM-HF) [9,50].